Brigatinib is a tyrosine kinase inhibitor that blocks ALK autophosphorylation and downstream signaling, and also acts on ROS1, IGF-1R, FLT3 and EGFR mutants in vitro.
Summary written with AI from the sources listed at the end of this page.
ALK-positive metastatic non-small cell lung cancer
From the indications section of the FDA label (version of Jan 12, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.